Phase I feasibility study of Olaparib in combination with loco-regional radiotherapy in head and neck squamous cell carcinoma

Purpose: PARP-inhibitors have potent radiosensitizing properties in pre-clinical models. To identify the maximum tolerated dose (MTD) of the PARP-inhibitor Olaparib in combination with radiotherapy in patients with head and neck cancer, a single institutional phase-I dose escalation trial was initia...

Descripció completa

Dades bibliogràfiques

Autors principals:	Arash Navran, Abrahim Al-Mamgani, Hester Elzinga, Rob Kessels, Conchita Vens, Margot Tesselaar, Michiel van den Brekel, Rosemarie de Haan, Baukelien van Triest, Marcel Verheij
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-01-01
Col·lecció:	Clinical and Translational Radiation Oncology
Matèries:	PARP inhibitor Olaparib Radiosensitization HNSCC Radiotherapy Feasibility
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2405630823001234
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!